Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979276 · ClinicalTrials.gov registry record · Phase 1
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01979276 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 4 participants.
The verdict
NCT01979276, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This clinical trial is for subjects with multiple myeloma that has returned after treatment (relapsed) or did not respond to prior treatment (refractory). The study is in two parts, Phase I and Phase II. Phase I will determine the maximum tolerated dose of romidepsin in combination with pomalidomide and dexamethasone. The purpose of Phase II is to evaluate the effectiveness of combining romidepsin with pomalidomide and dexamethasone. The hypothesis is that overall response in a cohort of patients treated with romidepsin + pomalidomide + dexamethasone will be 60 percent.
Interventions
- DRUG Dexamethasone
- DRUG Romidepsin
- DRUG pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01979276
The ClinicalTrials.gov registry entry for NCT01979276 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01979276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01979276 about?
NCT01979276 is a clinical study titled "Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma". This clinical trial is for subjects with multiple myeloma that has returned after treatment (relapsed) or did not respond to prior treatment (refractory). The study is in two parts, Phase I and Phase II. Phase I will determine the maximum tolerated dose of romidepsin in combination with pomalidomide...
What is the current status of trial NCT01979276?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2013-11. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01979276?
The interventions under investigation include: Dexamethasone (DRUG), Romidepsin (DRUG), pomalidomide (DRUG).
Who is sponsoring clinical trial NCT01979276?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.